What is the important information in the instructions for use of larotrectinib?

Larotrectinib is a targeted therapy drug that is a TRK inhibitor and is mainly used to treat NTRK gene fusion-positive tumors, including many different types of tumors, such as non-small cell lung cancer (NSCLC), liver cancer, soft tissue sarcoma, etc. The drug blocks cell proliferation and tumor growth caused by NTRK gene fusion by inhibiting the activity of TRK protein. The following is a detailed introduction to some important information in the instructions for use of larotrectinib.

1. Indications and treatment goals

The main indication of larotrectinib is the treatment ofNTRK gene fusion-positive tumors. These tumors are usually caused by the fusion of the NTRK gene with other genes to produce fusion proteins, which in turn activate cell proliferation signals, leading to cancer. As a TRK inhibitor, larotrectinib can selectively target and inhibit TRK fusion proteins, thereby effectively treating this type of tumor. Indications include but are not limited to:

Advanced or metastaticNTRK gene fusion-positive tumors in adults and children.

Patients with NTRK fusion such as non-small cell lung cancer (NSCLC), liver cancer, soft tissue sarcoma, etc.

2. Usage and dosage

The usual dose of larotrectinib is usually a once-daily oral dose for adults and children (12 years and above). The recommended dose for adults is 100 mg. The dose can be adjusted according to the patient's tolerance. During treatment, patients should strictly follow the medication regimen according to the doctor's instructions.

Adults: The recommended starting dose is100 mg once daily. For patients with obvious drug resistance or adverse reactions, the dose can be adjusted appropriately.

Children (12 years and older): Adjust dose based on body weight, usually 4 mg per kilogram of body weight once daily.

Larotrectinib can be taken with or without food, but to ensure drug absorption, it is recommended to take it at a fixed time each day.

3. Contraindications and Precautions

Contraindications to larotrectinib include:

Contraindicated in patients allergic to larotrectinib or any component of the drug.

Pregnant or breastfeeding women should avoid using larotrectinib because of the potential harm to the fetus or infant. If used, it must be done under the strict guidance of a doctor.

Patients should pay special attention to the following when using larotrectinib:

Liver function monitoring: Larotrectinib has a certain impact on liver function. Especially when used in patients with hepatic insufficiency, liver function needs to be monitored regularly to ensure liver health.

QTInterval prolongation: Larotrectinib may cause QT interval prolongation. Caution should be used when using it in patients with a history of heart disease, and necessary ECG monitoring should be performed.

Gastrointestinal discomfort: Patients may experience mild to moderate gastrointestinal discomfort symptoms, such as nausea, vomiting, etc. The dose needs to be adjusted appropriately or symptomatic treatment should be taken according to the patient's specific situation.

4. Side effects and adverse reactions

Some patients may experience adverse reactions during treatment with larotrectinib. Common side effects include:

Fatigue: Most patients may experience some degree of fatigue, but this usually resolves over a short period of time.

Abnormal liver function: Liver insufficiency, ALT/AST elevation, etc. are one of the common adverse reactions of larotrectinib, and liver function needs to be monitored regularly.

Gastrointestinal discomfort: Gastrointestinal symptoms such as nausea, vomiting, and loss of appetite are relatively common and are usually mild to moderate. Patients can adjust their diet or drug dosage as needed.

Less common serious side effects includeQT prolongation of the QT interval, allergic reactions, etc. If these symptoms occur, your doctor should be informed immediately and treated accordingly.

5. Drug Interactions

Larotinib may interact with other drugs. In particular, drugs that affect the CYP3A enzyme system may affect the plasma concentration of larotrectinib. Patients should avoid using larotinib with potent CYP3A enzyme inhibitors (such as ketoconazole, itraconazole, etc.) and potent CYP3AEnzyme inducers (such as rifampicin, phenobarbital, etc.) are used in combination. In addition, when using other chemotherapy drugs, you should consult your doctor to ensure the safety of the combined use of the drugs.

6. Long-term use monitoring

While using larotrectinib, patients should regularly undergo blood tests, liver function tests, electrocardiogram tests, etc. to ensure the safety and effectiveness of the treatment. Especially for patients with a history of heart disease, cardiac monitoring is particularly important.

In general, Larotrectinib (Larotrectinib), as a targeted therapy drug, is mainly used to treat NTRK gene fusion-positive tumors. Its use can significantly improve patient outcomes, especially for patients with advanced or metastatic tumors. Despite the remarkable efficacy, patients still need to pay attention to potential side effects and interactions with other drugs during use, monitor their physical condition regularly, and follow the doctor's guidance for treatment.

Reference materials:https://www.vitrakvi.com/